Mycophenolate mofetil: fully utilizing its benefits for GvHD prophylaxis.
about
Sensitive and validated LC-MS/MS methods to evaluate mycophenolic acid pharmacokinetics and pharmacodynamics in hematopoietic stem cell transplant patients.Clinical Pharmacokinetics of Mycophenolic Acid in Hematopoietic Stem Cell Transplantation Recipients.Mycophenolate-based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative-related donor stem cell transplantation.Mycophenolate mofetil use after unrelated hematopoietic stem cell transplantation for prophylaxis and treatment of graft-vs.-host disease in adult patients in Japan.Clinical outcomes of allogeneic stem cell transplantation for relapsed or refractory follicular lymphoma: a retrospective analysis by the Fukuoka Blood and Marrow Transplantation Group.Population pharmacokinetics and pharmacodynamics of mycophenolic acid using the prospective data in patients undergoing hematopoietic stem cell transplantation.Monitoring mycophenolate mofetil is necessary for the effective prophylaxis of acute GVHD after cord blood transplantation.Use of mycophenolate mofetil and a calcineurin inhibitor in allogeneic hematopoietic stem-cell transplantation from HLA-matched siblings or unrelated volunteer donors: Japanese multicenter phase II trials.Reduced-dose methotrexate in combination with tacrolimus was associated with rapid engraftment and recovery from oral mucositis without affecting the incidence of GVHD.Pharmacokinetic Variability of Mycophenolic Acid in Pediatric and Adult Patients With Hematopoietic Stem Cell Transplantation.Risk factors for hypogammaglobulinemia after allo-SCT
P2860
Q35549667-4B589CD1-BDBA-4821-BD24-AF701D1E1A07Q38817096-6CFAF852-84BE-4F69-A550-15DACBB5C0F0Q41525058-EB5B67DA-0731-4F64-8080-AEC67C8E8232Q43522314-19132907-9A0A-4894-8D18-6F5D65584DC4Q44065098-6A1DCC69-C3F6-407D-B681-AD5CEFC2E041Q47678205-EB2082CB-3880-4BD7-A8B4-45E07C953205Q48253938-0582ED5E-F859-4E7F-AEA6-9B0052C0382BQ52814358-6116F9A4-1693-4458-9DE0-B5780BAE2408Q53113415-47D99A24-BB03-4A55-B5C0-110AF15D7A2CQ53126891-3D974F6E-4984-4913-8CCE-4350757AC6DAQ58470540-34D8A69E-92B6-4027-9DF6-7E96BBBFF7EC
P2860
Mycophenolate mofetil: fully utilizing its benefits for GvHD prophylaxis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Mycophenolate mofetil: fully utilizing its benefits for GvHD prophylaxis.
@en
type
label
Mycophenolate mofetil: fully utilizing its benefits for GvHD prophylaxis.
@en
prefLabel
Mycophenolate mofetil: fully utilizing its benefits for GvHD prophylaxis.
@en
P2093
P2860
P1476
Mycophenolate mofetil: fully utilizing its benefits for GvHD prophylaxis
@en
P2093
Kentaro Minagawa
Motohiro Yamamori
Yoshio Katayama
P2860
P2888
P356
10.1007/S12185-012-1086-X
P577
2012-05-17T00:00:00Z
P5875
P6179
1049970375